论文部分内容阅读
目的:研究S100P蛋白在人肾原发透明细胞癌中的表达情况,并探讨其临床意义。方法:应用免疫组织化学SP法检测40例肾透明细胞癌及其癌旁肾组织、10例正常肾组织和8例转移性肾透明细胞癌组织中S100P蛋白的表达情况,结合患者临床病理资料进行分析,并探讨该蛋白在肾透明细胞癌发生发展中的作用。结果:S100P蛋白在正常及癌旁肾组织中呈弱表达且表达率较低,分别为10%和7.5%,而在原发肾透明细胞癌组织中的表达呈明显上调,为77.5%(χ2=45.187,P<0.01),阳性表达强度以弱-中度为主。S100P蛋白在转移性肾透明细胞癌组织中表达水平较原发癌显著降低,为12.5%(χ2=12.675,P<0.01);在晚期肾透明细胞癌组织中的表达率显著降低,与早期组比较差异有统计学意义(χ2=4.337,P<0.05)。结论:在原发性肾透明细胞癌组织中,S100P蛋白表达水平较正常组织明显上调,而在发生其他脏器转移的组织中显著降低。可见S100P蛋白可能在恶性肾肿瘤的发生发展中扮演重要角色,进一步深入研究有助于为肾透明细胞癌的诊疗开辟新思路。
Objective: To investigate the expression of S100P protein in human primary clear cell carcinoma and its clinical significance. Methods: Immunohistochemical SP method was used to detect the expression of S100P protein in 40 cases of clear cell renal cell carcinoma and its adjacent tissues, 10 cases of normal renal tissues and 8 cases of metastatic renal clear cell carcinoma. Combined with the clinicopathological data Analysis and explore the role of the protein in the occurrence and development of renal clear cell carcinoma. Results: The S100P protein was weakly expressed in the normal and paracancer tissues and the expression rates were lower (10% and 7.5%, respectively), but significantly higher in primary renal clear cell carcinoma tissues (77.5%, χ2 = 45.187, P <0.01). The positive expression intensity was mainly weak-moderate. The expression of S100P protein in metastatic renal clear cell carcinoma was significantly lower than that in primary carcinoma (12.5%, χ2 = 12.675, P <0.01), and was significantly lower in advanced renal clear cell carcinoma tissues than that in early stage The difference was statistically significant (χ2 = 4.337, P <0.05). Conclusion: The expression of S100P protein is significantly up-regulated in primary renal clear cell carcinoma tissues compared with normal tissues, but significantly lower in tissues with other organ metastases. It can be seen that S100P protein may play an important role in the occurrence and development of malignant renal neoplasm. Further study will help to open up new ideas for diagnosis and treatment of renal clear cell carcinoma.